BusinessPeregrine Pharmaceuticals Announces Appointment of Patrick Walsh to Board of Directors of Peregrine and Avid BioservicesBy Nasdaq OMXOct 24, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid BioservicesBy Nasdaq OMXOct 19, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent DevelopmentsBy Nasdaq OMXSep 11, 2017, 8:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid BioservicesBy Nasdaq OMXSep 11, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed GlioblastomaBy Nasdaq OMXSep 7, 2017, 12:10 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXSep 5, 2017, 8:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2017 and Recent DevelopmentsBy Nasdaq OMXJul 14, 2017, 8:13 PM UTC
BusinessPeregrine to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2017 After Market Close on July 14, 2017By Nasdaq OMXJul 7, 2017, 8:05 PM UTC
